Amgen’s Kyprolis approved for multiple myeloma by NICE

Amgen's multiple myeloma drug Kyprolis has been approved by the UK's National Institute for Health and Care Excellence (NICE).

The regulator has ratified the drug for routine prescription via the NHS after an independent NICE committee found that the therapy does not cause serious side effects such as chronic pain from damaged tissue to the same extent as current treatments.

It will be made available for patients with multiple myeloma whose cancer has come back after one round of therapy, provided that their previous treatment did not include the drug bortezomib.

NICE estimates that 2,200 patients a year with multiple myeloma will benefit from access to this tolerable new treatment through the NHS following this approval.

Tony Patrikios, executive medical director of Amgen in the UK and Ireland, said: "We know that time free of disease is precious and are committed to advancing care for people with this difficult-to-treat blood cancer."

This comes after the firm applied for US and European regulatory approval earlier this month to include additional overall survival data on the label for Kyprolis, in order to offer clearer guidance on its benefits.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.